Leukocyte interleukin with cyclophosphamide, indomethacin, and zinc for neoadjuvant therapy of squamous cell carcinoma of the head and neck

Leukocyte interleukin (LI) in combination with cyclophosphamide, indomethacin, and zinc is in clinical development for previously untreated, locally advanced squamous cell carcinoma of the head and neck (SCCHN) of the oral cavity and soft palate. SCCHN is a cancer that begins in the squamous cells (thin, flat cells that line various organs and skin) in areas of head and neck, including nasal cavity, sinuses, lips, mouth, salivary glands, throat and voice box. Locally advanced means that cancer has grown outside the area it started in but has not yet spread to other parts of the body. With current standard of care, most patients with SCCHN still experience disease recurrence or develop distant metastases (spread to distant organs or lymph nodes), therefore novel treatment options are needed.